NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
LataMed AI's Planned Expansion into Colombia: Key Questions Answered
LataMed AI Corp. (OTC: LMED) has commenced preliminary due diligence and strategic planning for expansion into Colombia, aiming to establish a subsidiary and deploy its digital healthcare platform. This move supports its broader Latin American strategy to improve healthcare access through AI and telehealth in underserved markets.
The announcement outlines the company's initiation of preliminary due diligence and strategic planning to expand into Colombia by establishing a subsidiary and deploying its digital healthcare platform.
The initial phase includes evaluating corporate, regulatory, legal, operational, and commercial requirements for establishing a Colombian operating subsidiary and supporting future deployment of the digital healthcare platform.
Management believes Colombia represents an attractive long-term market as part of its broader Latin American expansion strategy, focusing on improving healthcare accessibility in underserved regions.
The review will cover corporate formation, regulatory compliance, healthcare technology implementation, strategic partnerships, local operational infrastructure, and other market entry considerations.
LataMed AI is a development-stage digital health and AI technology company focused on telehealth infrastructure, healthcare analytics, and care coordination solutions for emerging markets.
He stated that Colombia represents an important strategic opportunity and that the company is in early stages of evaluating market entry, emphasizing the need to establish a proper foundation before expanding.
The company expects to provide additional updates as material developments occur, after completing the required corporate, regulatory, and operational review.
More information is available at https://latamed.ai, the company’s official social media channels, and its SEC filings at www.sec.gov.